Point72 Asset Management L.P. Takes $3.69 Million Position in Monopar Therapeutics Inc. (NASDAQ:MNPR)

Point72 Asset Management L.P. acquired a new position in Monopar Therapeutics Inc. (NASDAQ:MNPR - Free Report) in the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm acquired 167,892 shares of the company's stock, valued at approximately $3,694,000. Point72 Asset Management L.P. owned 2.75% of Monopar Therapeutics at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also bought and sold shares of the stock. Janus Henderson Group PLC purchased a new stake in Monopar Therapeutics in the fourth quarter worth about $23,435,000. RA Capital Management L.P. purchased a new position in shares of Monopar Therapeutics during the fourth quarter valued at approximately $11,247,000. Adage Capital Partners GP L.L.C. purchased a new position in shares of Monopar Therapeutics during the fourth quarter valued at approximately $13,182,000. ADAR1 Capital Management LLC purchased a new position in shares of Monopar Therapeutics during the fourth quarter valued at approximately $2,861,000. Finally, Geode Capital Management LLC lifted its holdings in shares of Monopar Therapeutics by 174.4% during the fourth quarter. Geode Capital Management LLC now owns 38,596 shares of the company's stock valued at $849,000 after purchasing an additional 24,530 shares during the last quarter. 1.83% of the stock is currently owned by hedge funds and other institutional investors.

Insider Activity

In other news, major shareholder Tactic Pharma Llc sold 33,334 shares of the business's stock in a transaction on Wednesday, April 2nd. The shares were sold at an average price of $35.00, for a total transaction of $1,166,690.00. Following the completion of the sale, the insider now owns 822,255 shares of the company's stock, valued at $28,778,925. The trade was a 3.90% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this link. Insiders own 20.50% of the company's stock.

Monopar Therapeutics Stock Performance

Shares of MNPR traded up $0.01 on Friday, hitting $35.45. 14,864 shares of the stock traded hands, compared to its average volume of 359,452. The company has a market capitalization of $216.78 million, a PE ratio of -17.99 and a beta of 1.11. The business has a 50 day simple moving average of $37.91 and a 200 day simple moving average of $32.21. Monopar Therapeutics Inc. has a one year low of $1.72 and a one year high of $54.30.

Monopar Therapeutics (NASDAQ:MNPR - Get Free Report) last announced its quarterly earnings results on Tuesday, May 13th. The company reported ($0.38) earnings per share for the quarter, beating the consensus estimate of ($0.65) by $0.27. On average, equities analysts expect that Monopar Therapeutics Inc. will post -1.65 earnings per share for the current year.

Wall Street Analysts Forecast Growth

Several research firms have recently issued reports on MNPR. Jones Trading reiterated a "hold" rating on shares of Monopar Therapeutics in a report on Wednesday, April 2nd. Wall Street Zen upgraded shares of Monopar Therapeutics from a "sell" rating to a "hold" rating in a report on Thursday. HC Wainwright reiterated a "buy" rating and set a $40.00 target price on shares of Monopar Therapeutics in a report on Tuesday, April 1st. Finally, Piper Sandler reiterated an "overweight" rating and set a $76.00 target price on shares of Monopar Therapeutics in a report on Wednesday, March 19th. Two analysts have rated the stock with a hold rating and three have assigned a buy rating to the company. According to MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and a consensus price target of $55.33.

About Monopar Therapeutics

Monopar Therapeutics Inc, a clinical-stage biopharmaceutical company, engages in developing therapeutics for the treatment of cancer in the United States. Its lead product candidate in development is Validive, a clonidine hydrochloride mucobuccal tablet that is in Phase 2b/3 clinical trial for the prevention of chemoradiotherapy induced severe oral mucositis in patients with oropharyngeal cancer.